Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Other Gross PP&E Adjustments (2019 - 2026)

Sunshine Biopharma filings provide 5 years of Other Gross PP&E Adjustments readings, the most recent being $291403.0 for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 645.2% to $291403.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $291403.0, a 645.2% increase, with the full-year FY2025 number at $291403.0, up 645.2% from a year prior.
  • Other Gross PP&E Adjustments hit $291403.0 in Q4 2025 for Sunshine Biopharma, up from $240067.0 in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $291403.0 in Q4 2025 to a low of -$728129.0 in Q1 2023.
  • Median Other Gross PP&E Adjustments over the past 4 years was -$282354.0 (2022), compared with a mean of -$273702.2.
  • Biggest five-year swings in Other Gross PP&E Adjustments: grew 17.56% in 2024 and later surged 645.2% in 2025.
  • Sunshine Biopharma's Other Gross PP&E Adjustments stood at -$282354.0 in 2022, then surged by 67.8% to -$90915.0 in 2023, then skyrocketed by 41.21% to -$53449.0 in 2024, then surged by 645.2% to $291403.0 in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $291403.0 (Q4 2025), $240067.0 (Q3 2025), and $158163.0 (Q2 2025) per Business Quant data.